Vicore Pharma Holding (NASDAQ:VCRE) Stock Short Interest Drops 75.7%

Vicore Pharma Holding (NASDAQ:VCRE) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 1,028 shares, a decrease of 75.7% from the September 30th total of 4,238 shares. Based on an average daily volume of 27,277 shares, the days-to-cover ratio is currently 0.0 days.

Vicore Pharma Stock Down 0.5%

Shares of NASDAQ:VCRE opened at $9.35 on Wednesday. Vicore Pharma has a fifty-two week low of $7.88 and a fifty-two week high of $17.80.

Vicore Pharma (NASDAQ:VCRE) last announced its quarterly earnings results on Friday, August 21st. The company reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $0.23 million for the quarter.

Analysts Set New Price Targets

VCRE has been the subject of a number of analyst reports. Weiss Ratings initiated coverage on Vicore Pharma in a research note on Thursday, October 8th. They issued a “sell (e-)” rating for the company. Jefferies Financial Group started coverage on Vicore Pharma in a research note on Friday, October 9th. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Wall Street Zen upgraded Vicore Pharma to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $25.00.

About Vicore Pharma

Vicore Pharma is a Swedish biopharmaceutical company focused on developing medicines for severe respiratory and pulmonary diseases. The company’s research is centered on treatments intended to address the underlying disease processes associated with conditions such as idiopathic pulmonary fibrosis and other forms of progressive lung fibrosis.

Vicore’s lead investigational program is buloxibutid, formerly known as C21, an orally administered small-molecule agonist of the angiotensin II type 2 receptor.